ABSTRACT DNA-based drug delivery vehicles have displayed promise for the delivery of intercalating drugs. Here, we demonstrate that oligonucleotides modified with an alkyl chain can bind to human serum albumin, mimicking the natural binding of fatty acids. These alkyl-DNA-albumin complexes display excellent serum stability and are capable of strongly binding doxorubicin.
INTRODUCTION 2
Nature has evolved highly efficient transport processes for regulating nutrients, waste products and exogenous compounds to maintain homeostasis within the human body. 1 New therapeutics therefore often require optimization to ensure a positive clinical outcome. For example, pharmacokinetics may be enhanced by derivatization of the therapeutic or incorporation into synthetic carriers such as micelles, nanoparticles and liposomes. [2] [3] [4] Natural particulates such as viruses and proteins are of increasing interest as delivery platforms for biologics and small drugs since they have the ability to pass through cell barriers, evade clearance by the body and often have an established pharmacokinetic profile. [5] [6] [7] Human serum albumin (HSA) has been extensively studied and developed as a delivery platform towards this end with albumin-binding formulations such as Abraxane (HSA-bound paclitaxel) and Levemir (Myristic acid insulin conjugate) already in the clinic and Aldoxorubicin (HSA-bound doxorubicin) in Phase III clinical trials for soft tissue sarcoma. 8 Albumin has favourable properties for therapeutic optimization including a long half-life, high abundance in plasma, a well-defined structure, and excellent binding properties for both endogenous and exogenous compounds. [9] [10] [11] [12] Albumin is also of increasing importance for the delivery of cytotoxics since its uptake and metabolism is upregulated in tumor cells [13] [14] [15] and its accumulation in tumor neo-vasculature by the Enhanced Permeation Retention (EPR) effect. 16, 17 The ability of intercalating cytotoxics to form strong physical complexes with double stranded oligonucleotides (dsODN) 18 has been studied as a potential prodrug strategy in oncology. 19, 20 However, poor stability and low cellular uptake of oligonucleotides in vivo still provide a major barrier clinical translation. Recent developments in nucleoside chemistry and the assembly of highly elaborate DNA structures at the nanoscale have come some way in addressing these 3 issues. 21 However, these approaches need to be simplified to facilitate scale-up and minimize the potential cost of therapy. [22] [23] [24] [25] We have previously investigated the effects of polymer conjugation to both 5' ends of a 22mer dsODN and the effects on delivery of the intercalating cytotoxic doxorubicin. 20 The PEG conjugation was found not to affect dsODN-drug affinity while significantly improving the stability of the dsODN against nucleases. However, PEGylated dsODNs were found to be less effective than free doxorubicin and were unable to enhance sensitivity of a drug resistant cell line.
Herein, we describe a pro-drug inspired by the ability of albumin to transport fatty acids into cells to deliver doxorubicin using an alkylated dsODN as a fatty acid mimic ( Figure 1a ). The dsODNs were modified with alkyl chains of various lengths and functionalities which were screened and selected on the merit of their albumin binding. The best candidates were evaluated in vitro in terms of stability, dsODN cellular uptake and doxorubicin delivery. The linker design played a pivotal role in determining albumin binding, stability and cellular uptake of the carrier with the introduction of a small spacer between the alkyl and dsODN chains affecting albumin binding, stability, cellular uptake and the ultimate cytotoxicity of a doxorubicin-loaded conjugates. A selected alkyl-dsODN conjugate demonstrated rapid uptake of the dsODN carrier and intracellular doxorubicin levels which were comparable to that of the free drug.
MATERIALS AND METHODS
Oligonucleotides (HPLC purified) were purchased from Biomers.net GmbH (Ulm, Germany) and used without further purification. Oregon Green® 488 Carboxylic Acid, Succinimidyl Ester, 5-isomer was purchased from Life Technologies. PD SpinTrap G-25 columns, Disposable PD-10
Desalting Columns, Biacore CM5 sensor chip and HBS-P buffer were purchased from GE using a TSKgel G3000SWXL (TOSOH) column at 1 mL/min. UV absorbance was recorded at 220 nm.
MALDI analysis
Matrix-assisted laser desorption/ionization time-of flight (MALDI-TOF) mass spectrometry was performed on a Bruker MALDI-TOF Ultra Flex III spectrometer operated in reflective, negative ion mode. 3-HPA containing DAHC was used as the matrix for oligonucleotide analysis. Briefly, a saturated solution of 3-HPA (50 mg/mL) was prepared by adding 25 µg of 3-HPA to 500 µL of 50% ACN/water. 25 µL of DAHC solution (100 mg/mL) was added to 225 µL of the 3-HPA solution, to give a final DAHC concentration of 10 mg/mL. Equal volumes of matrix solution and ODN solution (0.2 mM) were mixed and 2 µL of the mixture was spotted onto the MALDI plate and allowed to dry.
Synthesis of octadecanol-DSC (C18-DSC)
1-Octadecanol (5 g, 0.0184 mol) was weighed out and placed in a sealed round bottom flask.
The lipid was dissolved in anhydrous THF (100 mL) and the solution cooled down to 0C in an ice bath. DSC (9.47 g, 0.0369 mol) and Et3N (4.67 g, 0.046 mol) were added to the solution which was allowed to warm to room temperature (ca. 20 °C) and then left to react overnight (16 h. 
Synthesis of tetradecanol-DSC (C14-DSC)
1-Tetradecanol (1 g, 0.0047 mol) was weighed out and placed in a sealed round bottom flask.
The lipid was dissolved in anhydrous THF (100 mL) and the solution cooled down to 0C in an ice bath. DSC (2.99 g, 0.012 mol) and Et3N (1.62 g, 0.012 mol) were added to the solution which was allowed to warm to room temperature (ca. 20°C) and then left to react overnight (16 h.). The resulting suspension was filtered to remove solids and volatiles were removed under reduced pressure. C14-DSC was precipitated from water, collected by filtration, re-dissolved in THF and precipitated in water again. This procedure was repeated twice. C14-DSC was finally dissolved 8 in DCM and dried over MgSO4 before filtration, removal of solid and evaporation of DCM under reduced pressure. C14-DSC was subsequently recovered as a white powder (1.2g, 75%
yield, >85% purity, unreacted tetradecanol (<15%) present after purification). 
Synthesis of oleyl alcohol-DSC (C18:1-DSC)
1-Oleyl alcohol (1 g, 0.0032 mol) was weighed out and placed in a sealed round bottom flask.
The lipid was dissolved in anhydrous MeCN (100 mL) and the solution cooled down to 0C in an ice bath. DSC (2.02 g, 0.0079 mol) and Et3N (1.10 g, 0.079 mol) were added to the solution which was allowed to warm to room temperature (ca. 20°C) and then left to react overnight (16 h.). The resulting suspension was filtered to remove solids and volatiles were removed under reduced pressure. The product was extracted into hexane, insoluble material removed by filtration and volatiles removed under reduced pressure. C18:1-DSC was isolated as a yellowish oil (0.6 g, 46% yield, >92% purity). 
Oligonucleotide conjugations -Generic protocol
ODN A (5'-taa cag gat tag cag agc gag g-3', 5'-Modification: Aminolink C6) or ODN B (5'-cct cgc tct gct aat cct gtt a-3', 5'-Modification: Aminolink C6) was dissolved in isotonic PBS pH 7.4 (2.5 mg/mL) and subsequently transferred to a 15 mL Falcon tube. The DSC alkyl chain was 9 dissolved in THF (0.7 mg/mL, 5 eq. to the ODN) and added to ODN solution. The mixture was allowed to react for 72 h. at room temperature. Conjugate formation was monitored by HPLC.
After 72 h. the THF was removed under reduced pressure and the aqueous solution concentrated.
The remaining solution was transferred to a 1.5 mL Eppendorf tube and centrifuged in order to remove insoluble free alkyl chains. The alkyl-ODN conjugate was subsequently purified by semi-preparative HPLC and lyophilized. Lyophilized ODN was resuspended in DNase free water (1 mL) and the recovery estimated from the optical density at 260 nm, the solution was subsequently aliquoted into sterile Eppendorfs and lyophilized. The purified ODN-conjugates were analysed using HPLC and MALDI-TOF analysis.
Oligonucleotide Oregon Green (OG) conjugation
ODN B (5'-cct cgc tct gct aat cct gtt a-3', 5'-Modification: Aminolink C6) was dissolved in isotonic PBS pH 7.4 (2.5 mg/mL, 2.5 mL, 0.93mmol) and subsequently transferred to a 15 mL falcon tube. Oregon Green 488 Carboxylic Acid, Succinimidyl Ester (OG488) was dissolved in anhydrous DMSO at a concentration of 5 mg/mL for the fluorophore. A sample (0.5 mL) of the fluorophore solution (2.5 mg, 4.6 mmol) was added to the ODN solution and allowed to react at room temperature for 2 days. The reaction was monitored by HPLC. After 2 days the DMSO was removed using a PD-10 Desalting Column (gravity protocol), the aqueous solution was concentrated under reduced pressure and the OG-ODN conjugate purified by semi-preparative 
Hybridization of DNA strands
Strands were hybridized in annealing buffer which consisted of 10 mM Tris, 50 mM NaCl and 1 mM EDTA pH 7.5. For the hybridization the strands were mixed in equimolar quantities to
give a final concentration of ~75 µM of each strand and placed in a water bath at 95C for 5 minutes. The water bath was then turned off and allowed to cool down to room temperature. The annealed strands were desalted using a PD SpinTrap G-25 column (gravity protocol), oligonucleotide concentration was measured using optical density at 260 nm (1 OD = 30 ug/mL).
Annealing was verified using PAGE analysis. The oligonucleotide solutions were then aliquoted, lyophilized and kept in freezer before usage. Table 2 . Hybridization of oligonucleotide strands.
Polyacrylamide gel electrophoresis (PAGE)
Polyacrylamide gel electrophoresis (PAGE) analysis was carried out at 180 mV using a 15% acrylamide running gel. Native gels were prepared using acrylamide-bis-acrylamide (29:1) and TBE (Tris-borate-EDTA) solutions. Samples were prepared by dilution in native loading buffer containing glycerol and bromophenol blue. Quantities (5 µg) representing equivalence of each oligonucleotide was loaded per well. In instances where human serum albumin was used, 2 molar equivalents of the protein were added to the dsODN. IDT Oligo Length Standard 10/60 was used a size marker for the gels. The oligonucleotide/polymer bands were visualized using methylene blue staining.
Affinity of doxorubicin HCl to hybridized oligonucleotide strands
Fluorescence spectroscopy method 19 
Surface plasmon resonance analysis
Surface plasma resonance (SPR) analysis was carried out on a Biacore 3000 instrument using a C18-dsODN, C18:1-dsODN and C14-dsODN were measured across a concentration range from 28 µM to 0 M. C18-SP-dsODN was measured from 28 µM down to 0 µM. Affinity constants were determined using the BiaEvaluation Software.
Stability of oligonucleotides
The hybridized oligonucleotide strands were incubated at an oligonucleotide concentration of 0.83 µg/mL in phosphate buffer saline containing 20 % fetal calf serum (FCS). The stability of unmodified dsODN was compared to that of alkyl conjugated ODN strands. Solutions were incubated in a water bath at 37 C with mild agitation. Samples were taken for each oligonucleotide at 0, 24, 48 and 72 h. respectively. At each time point 9 µL samples were taken.
The samples were rapidly cooled using liquid nitrogen and kept in a freezer at -20 C until analysis by gel electrophoresis. The strands were separated on a 15% non-denaturing acrylamide gel. The samples were diluted with 12 µL of native loading buffer. An aliquot (9 µL) of the diluted sample was loaded per well, each sample was loaded in duplicate. PAGE was carried out at 160 mV. The oligonucleotide/polymer bands were visualized using methylene blue. Stability of the unmodified and C18 modified strands was determined by comparing the intensity of the ODN bands to the ODN intensity at T0 (100%). Stability of the C18-SP-DsODN was estimated from T48 (100%) since it was fully protein bound before 48 h (no free dsODN or DNA fragments were observed in the gel for the C18-SP-dsODN modification while the stable complex did not 13 penetrate the gel fully). The ratio of albumin to dsODN in the gel was determined by comparing the intensities of the unmodified dsODN band to the albumin band at T0. This value was used to calculate the percentage of bound dsODN in the gel for each time point. It was assumed that the binding of the alkylated dsODN to the albumin did not affect the protein staining and that protein denaturation was minimal over the course of the experiment. Band intensity was estimated using the graphical analysis software GelQuantNet.
Competitive binding assay
Solutions of C18-dsODN and C18-SP-dsODN (92 µM) were prepared in isotonic PBS. 
Melting temperature analysis of dsODNs
Thermal stability analysis of dsODN (Tm analysis) was carried out using a Beckman DU 800 UV/Vis Spectrophotometer with a Peltier Temperature Controller. UV absorbance was recorded at 260nm. The dsODNs were heated from 20 C to 85 C using a temperature gradient of 1C/min and UV readings were recorded every 0.5 C. dsODN melting point was determined by first derivative analysis of the graph. The dsODNs were dissolved in isotonic PBS pH 7.4, a dsODN concentration of ~12 µg/mL was used for the analysis. 
Mitochondria and rab5a colocalization
Cells were seeded on coverslip glass as described above. After 24 h., cells were infected with 
Cytotoxicity assay
Cells were seeded in 96 well plates at 7,000/well in complete media. Cells were incubated with the doxorubicin-loaded conjugates for 72 hours. After this time a rezasurin cell viability assay was conducted. 26 Briefly, Rezasurin solution was added to the media to a final concentration of 60 µM then incubated for 1 h. at 37 C. The fluorescence was measured using a Molecular Devices Flexstation 3 plate reader (λex = 585 nm, λem = 610 nm).
Uptake assays
Cells were seeded in 96 well plates in complete media at 10,000 cells/well. Doxorubicin loaded conjugates were prepared as described above and diluted to 3 μM DNA in MEM dNTP media then incubated for the stated time. Cells were washed thrice in PBS then doxorubicin or
Oregon green fluorescence was measured using Molecular Devices Flexstation 3 plate reader.
RESULTS AND DISCUSSION

Synthesis of alkylated dsODNs
Alkylated ODN conjugates were synthesized by adopting the method we have previously described for the PEGylation of ODNs. 20, 27 Alkyl alcohols were activated using N,Ndisuccinimidyl carbonate to form amino-reactive alkyl-succinimidyl carbonates (ASC). The activated alkyl derivatives were conjugated to the 5' end of amine modified ODN (Oligo A:
TAA CAG GAT TAG CAG AGC GAG G) (Figure 1b) . The oligonucleotide sequence and its complementary sequence were chosen on their ability to form a strong physical complex with doxorubicin as a dsODN. 20 The reaction was carried out in a 1:1 solution mixture of THF/PBS with an excess (>5 eq.) of the activated alkyl chain. Initial conjugations and screening were carried out for tetradecanol (C14), octadecanol (C18) and 3 cis-9-octadecenol (C18:1). For uptake/co-localization studies the 5' C6 amine-modified complementary strand (Oligo B: CCT
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CGC TCT GCT AAT CCT GTT A) was conjugated to NHS Oregon Green 488 (OG488) ( Figure   1c ). The reactions were monitored using HPLC and then purified by semi-preparative HPLC. All of the alkylation reactions achieved >95% conversion relative to the amine modified ODN.
However, the reaction between NHS OG488 and the complementary strand achieved ~50% conversion due to the rapid hydrolysis of the activated NHS ester under the synthetic conditions.
Alkylated and fluorophore-modified ODNs were purified by HPLC and recovered in moderate yield (35-50%). Low recovery after purification was attributed to the losses during sample preparation/filtration due to the low sample volumes. The purity of the modified ODNs was determined by HPLC and polyacrylamide gel electrophoresis (Figures S1/S2 and 1e and 1f) and the identity of the desired products confirmed by MALDI-TOF mass spectrometry (Table 1) . Alkylated ODN strands were annealed with unmodified complementary DNA to form a series of monoalkylated dsODN. PAGE analysis of the annealed strands confirmed that no free strand(s) were present after annealing (Figure 1e and   1f ). In order to confirm that albumin was able to bind monoalkylated-dsODN, PAGE analysis was performed in the presence of HSA. The C18-dsODN was completely bound to the albumin while the unsaturated C18:1 and C14 modified dsODNs were only partially bound under these conditions ( Figure 1f ). As expected, no binding was observed for the unmodified dsODN to albumin.
Albumin-binding of alkylated dsODNs
The disassociation constants (KD) for the alkyl-dsODN albumin complexes were determined by surface plasmon resonance (SPR) analysis. The surface of an SPR chip (CM5) was modified with albumin using standard EDC/NHS coupling chemistry. Samples containing a range of concentrations of the alkyl-dsODNs were injected over the albumin modified surface and the disassociation constants determined by the SPR response ( Figure S3 ). Curve fitting was performed assuming 1:1 stoichiometry, because the large size of the dsODN, ~7.5 nm length and ~2 nm diameter, 28 is expected to prevent multiple binding to albumin. Analysis by dynamic light scattering supported this assumption with no increase in complex size observed at higher alkyldsODN to albumin ratios and an average hydrodynamic diameter of 9 nm for both complexes ( Figure S4 ). The C18 derivative formed the highest affinity complex with albumin out of the three alkyl-dsODN conjugates. No binding response was observed for unmodified, "native" dsODN. Based on these results the C18-dsODN derivative was selected for further studies and optimization while the C14 and the unsaturated C18 derivatives were omitted from further testing based on their weaker albumin binding.
The crosslinking chemistry, and more importantly the length of linker, can play a pivotal role in determining the activity of a crosslinked macromolecular conjugate. 29 We hypothesized that the large size of dsODN (~7.5 nm length and ~2 nm diameter) 28 and close vicinity of the fatty acid moiety to the dsODN strand could have great impact on its affinity to albumin.
Consequently, a small spacer was placed between the alkyl chain and the ODN of the C18-dsODN conjugate and its effects examined (Figure 2a) . A diethylene glycol based linker, 2-(2-aminoethoxy)ethanol was conjugated to the C18 DSC-activated chain and the resulting free hydroxyl was activated again using DSC to produce the amine reactive C18-Spacer (C18-SP).
The C18-SP derivative was synthesized, purified and characterized as described for the previous alkyl-ODN derivatives.
The albumin binding of the two conjugates was compared using a competitive displacement assay. Albumin and each alkyl conjugate were mixed in a 1:1 molar ratio and equilibrated for 30 min. Complex formation was validated by size exclusion chromatography (SEC). Palmitic acid (1.25 eq, 1.75 eq and 2.5 eq.) was added to the complexes and the solution equilibrated for 30 minutes. After equilibration, the displacement of the albumin-alkyl dsODN complex by palmitic acid was subsequently determined by SEC (Figures 2b and S5) . The displacement assay confirmed that introduction of the spacer significantly improved the albumin binding. Around 35% of the C18-dsODN conjugate was displaced from albumin at the highest concentration of palmitic acid tested while in the case of the C18-SP-dsODN only 20% was displaced.
The stability of the two C18 dsODN conjugates and the unmodified dsODN were examined in presence of fetal calf serum over a period of 72 h. by PAGE analysis and quantified using image analysis (Figures 2c and S6) . In this experiment, the C18-SP-dsODN was the most stable of three dsODN constructs with ~87% remaining intact after 72 h. C18-dsODN and unmodified dsODN were both degraded more quickly with ~45% of each dsODN remaining after 72 h. The stability study also suggests that the initial degradation of the C18-dsODN was faster than that of the unmodified dsODN.
Examination of the PAGE gels ( Figure S6 ) used to determine DNA stability revealed a difference in albumin binding between the two C18 derivatives. The C18-SP-dsODN derivative largely remained albumin-bound for the first 48 h. and showed limited degradation. In contrast, the C18-dsODN derivative was only 40% albumin bound at the start of the experiment and therefore more rapidly degraded due to lower steric hindrance and thus higher accessibility to nucleases. The increased degradation observed for the C18-dsODN compared to the unmodified dsODN is not fully understood, but it is plausible that ODN-nuclease hydrophobic interactions are enhanced by the alkyl chain when it is not bound to the albumin. 30 The affinity of doxorubicin to the dsODN conjugates was determined by a fluorescence quenching protocol. 19 The affinity of doxorubicin to the dsODN was slightly enhanced by modification with alkylated dsODNs displaying slightly lower dissociation constants to the unmodified dsODN ( Figure S7 , KD = 110 ± 30 nM vs. 217 ± 91 nM ).
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Alkyl-modified dsODN uptake studies
The C18-dsODN, C18-SP-dsODN and unmodified dsODN were compared using in vitro cellbased assays to determine their uptake characteristics and ability to deliver doxorubicin efficiently into resistant cells. To assess cellular uptake, Oregon Green-labelled dsODNs were incubated with MCF-7 cells for 4 hours prior to quantification of cell-associated fluorescence levels ( Figure 3a) 21 and visualization by confocal microscopy in cells modified with fluorescently labelled organelle markers ( Figure 3b ). Unmodified dsODN was taken up at significantly lower levels than either alkyl-modified ODNs while the high affinity albumin binding variant dsODN-Spacer-C18 uptake was significantly (1-way ANOVA, p<0.01) higher than the C18 derivative (Figure 3a) .
Microscopy revealed partial colocalization of alkyl-modified conjugates with both the early endosome marker Rab5a and the mitochondria (Figure 3b ). Due to the highly charged and hydrophilic nature of the oligonucleotides, internalization of these particles is unlikely to occur by diffusion or 'flip-flop' across the plasma membrane as is common with fatty acid uptake. 31 Instead an active endocytic pathway is likely. Both albumin and fatty acids are known to be internalized into cells via multiple pathways. Albumin has been shown to be readily internalized via pinocytosis into Rab5 positive endosomes. [32] [33] [34] Therefore, due to the conjugates' high affinity for albumin and colocalization demonstrated in figure 3b this is a potential route of entry. Fatty acids have also been demonstrated to be internalized by fatty acid translocase CD36 via a novel, poorly defined endocytic pathway. 35, 36 Once internalized fatty acids are known to traffic effectively to the mitochondria where they provide a high energy source for the cell. 37, 38 Our data suggests that alkyl modification of DNA allows rapid cellular internalization of the complex with a proportion trafficking via Rab5a early endosomes and results in targeting of short DNA sequences to the mitochondria. Uptake studies were also performed in A549 cells and the results were consistent with MCF-7 cells ( Figure S10 ). 
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Incorporation of spacer restores DOX cytotoxicity
The cytotoxicity of doxorubicin-loaded dsODNs and unloaded dsODNs carriers was investigated in MCF7 cell line over 72 h. None of the drug free carriers demonstrated cellular toxicity and cellular growth was not enhanced when the cell media was supplemented with free nucleosides (Figure 5a ). 20 In conclusion, we have demonstrated that dsODNs modified with alkyl chains are successfully internalized into cells and trafficked to the mitochondria, mimicking the natural pathway for fatty acids. Trafficking of fatty acids to the mitochondria opens the possibility to specifically deliver therapeutic moieties to the organelle to treat mitochondrial disease. We also suggest that alkyl chain modification could prove beneficial for other applications, for example in mitochondrial DNA gene editing using technologies such as Crispr/Cas9 and TALEN. Specific cleavage of mitochondrial DNA has been achieved using modified versions of both systems although gene 28 replacement has not yet been demonstrated. 42, 43 Specific targeting of a therapeutic template DNA strand to the mitochondria during gene editing is likely to increase successful gene replacement and limit off target nuclear effects.
Incorporation of an additional spacer between the dsODN and alkyl chain (C18-SP-dsODN) increased albumin binding affinity and displayed excellent stability in serum over 72 h.
Incorporation of the spacer also restored doxorubicin-cytotoxicity to comparable levels as free doxorubicin due to successful delivery to the nucleus. 
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